Antifungal serum concentration monitoring: An update

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 17-25

  Goodwin, Megan I ^a   Drew, Richard H ^b,c  

^a CARILION CLINIC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Campbell University   (United States)

Author keywords

Azoles; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LONG ACTING DRUG; MICAFUNGIN; POSACONAZOLE; RIFABUTIN; RIFAMPICIN; RITONAVIR; VORICONAZOLE;

ADRENAL INSUFFICIENCY; ANEMIA; AREA UNDER THE CURVE; ASPERGILLOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANDIDA MENINGITIS; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROLYTE DISTURBANCE; ERYTHEMA MULTIFORME; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPLASMOSIS; HUMAN; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OROPHARYNX CANDIDIASIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ANTIFUNGAL AGENTS; AZOLES; ECHINOCANDINS; FLUCYTOSINE; HUMANS; MONITORING, PHYSIOLOGIC; MYCOSES;

EID: 37549028402     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm389     Document Type: Review

References (109)

1. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
2. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial blood-stream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
3. Trick WE, Fridkin SK, Edwards JR et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30.
4. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
5. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
6. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of blood-stream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
7. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521-6.
8. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
9. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clin Infect Dis 2001; 33 177-86.
10. Nguyen MH, Peacock JE Jr, Morris AJ et al. The changing face of candidemia: Emergence of non-Candida albicans species and anti-fungal resistance. Am J Med 1996; 100: 617-23.
11. Garey KW, Rege M, Pai MP et al. Time to initiation of flucona-zole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
12. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
13. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
14. Almyroudis NG, Sutton DA, Linden P et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-74.
15. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
16. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
17. Leather HL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 2006; 20: 267-87.
18. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43: 1060-8.
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice men. Clin Infect Dis 1998; 26: 1-10.
20. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-86.
21. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20: 679-97.
22. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-29.
23. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
24. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
25. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30 710-8.
26. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000; 30: 684-7.
27. Chapman SW, Bradsher RW Jr, Campbell GD Jr et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30: 679-83.
28. Galgiani JN, Ampel NM, Blair JE et al. Coccidioidomycosis. Clin Infect Dis 2005; 41: 1217-23.
29. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-25.
30. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 Suppl 1: 31-6.
31. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-6.
32. Wiederhold NP, Tam VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 469-73.
33. Andes D, Safdar N, Marchillo K et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006; 50: 674-84.
34. Hong Y, Shaw PJ, Nath CE et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006; 50: 935-42.
35. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N EngI J Med 2002; 346 225-34.
36. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
37. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-9.
38. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301: 126-31.
39. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000; 44: 938-42.
40. Karyotakis NC, Anaissie EJ. Efficacy of continuous flucytosine infusion against Candida Iusitaniae in experimental hematogenous murine candidiasis. Antimicrob Agents Chemother 1996; 40: 2907-8.
41. te Dorsthorst DT, Verweij PE, Meis JF et al. Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob Agents Chemother 2005; 49: 4220-6.
42. Vermes A, van Der SH, Guchelaar HJ. Flucytosine: Correlation between toxicity pharmacokinetic parameters. Chemotherapy 2000; 46: 86-94.
43. Stamm AM, Diasio RB, Dismukes WE et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcall meningitis. Am J Med 1987; 83: 236-42.
44. Bury RW, Mashford ML, Miles HM. Assay of flucytosine (5-fluorocytosine) in human plasma by high-pressure liquid chromatography. Antimicrob Agents Chemother 1979; 16: 529-32.
45. Block ER, Bennett JE. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother 1972; 1: 476-82.
46. Kaspar RL, Drutz DJ. Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother 1975; 7 462-5.
47. Dodds Ashley E, Lewis R, Lewis JS et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28-39.
48. Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006; 9: 483-8.
49. Raad II, Hachern RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
50. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-3.
51. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43: 2116-20.
52. Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9.
53. Csajka C, Decosterd LA, Buclin T et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001; 57: 723-7.
54. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungall susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
55. Pal MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-9.
56. Takakura S, Fujihara N, Saito T et al. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Micro Infect Dis 2004; 23: 380-8.
57. Lee SC, Fung CP, Huang JS et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44: 2715-8.
58. Clancy CJ, Yu VL, Morris AJ et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49 3171-7.
59. Anaissie EJ, Kontoyiannis DP, Huls C et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602.
60. Ng TK, Chan RC, Adeyemi-Doro FA et al. Rapid high performance liquid chromatographic assay for antifungal agents in human sera. J Antimicrob Chemother 1996; 37: 465-72.
61. Summers KK, Hardin TC, Gore SJ et al. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997; 40 753-64.
62. Debruyne D, Ryckelynck JP, Bigot MC et al. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector. J Pharm Sci 1988; 77: 534-5.
63. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61: 27-37.
64. Poirier JM, Berlioz F, Isnard F et al. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie 1996; 51: 163-7.
65. Van Peer A, Woestenborghs R, Heykants J et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-6.
66. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-7.
67. Van de Velde VJ, Van Peer AP, Heykants JJ et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-8.
68. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997; 50: 477-80.
69. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-51.
70. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 1989; 32: 103-8.
71. Sharkey PK, Rinaldi MG, Dunn JF et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991; 35: 707-13.
72. Hostetler JS, Heykants J, Clemons KV et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: Studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37: 2224-7.
73. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-63.
74. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13.
75. Purkins L, Wood N, Kleinermans D et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56: 17-23.
76. VFend (voriconazole). Prescribing Information. November 2006 (USA). New York, NY: Pfizer Pharmaceuticals.
77. Johnson LB, Kauffman CA. Voriconazole: A new triazole anti-fungal agent. Clin Infect Dis 2003; 36: 630-7.
78. Ikeda Y, Umemura K, Kondo K et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-8.
79. Desta Z, Zhao X, Shin JG et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58.
80. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
81. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
82. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: A dose escalation study. J Clin Pharmacol 2002; 42 395-402.
83. Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1986; 30: 418-22.
84. Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989; 33: 147-51.
85. Andes D, Marchillo K, Stamstad T et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-9.
86. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
87. Pennick GJ, Clark M, Sutton DA et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348-50.
88. Perea S, Pennick GJ, Modak A et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 2000; 44: 1209-13.
89. Noxafil (posaconazole). Prescribing information, October 2006 (USA). Kenilworth, NJ: Schering Corporation.
90. Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-22.
91. Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50: 1993-9.
92. Ullmann AJ, Comely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66.
93. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-42.
94. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
95. Noxafil (posaconazole). European prescribing information. March 2007 (European Union). Brussels, Belgium: Schering-Plough Europe.
96. Kim H, Kumari P, Laughlin M et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posacona- zole in human plasma. J Chromatogr 2003; 987: 243-8.
97. Krieter P, Flannery B, Musick T et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-51.
98. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
99. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.
100. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-5.
101. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
102. Krause DS, Reinhardt J, Vazquez JA et al. Phase 2 randomized dose-ranging study evaluating the safety efficacy of anidulafungin in invasive candidiasis candidemia. Antimicrob Agents Chemother 2004; 48: 2021-4.
103. Kartsonis NA, Saah AJ, Joy LC et al. Salvage therapy with caspofungin for invasive aspergillosis: Results from the caspofungin compassionate use study. J Infect 2005; 50: 196-205.
104. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomall amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351 1391-402.
105. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
106. Ernst EJ, Klepser ME, Emst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
107. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
108. Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
109. Center for Drug Evaluation and Research. Posaconazole (Noxafil®, Schering-Plough)-Clinical Pharmacology and Biopharmaceutics Reviews. Application 22-003, 22 December 2005. Available at: http://www.fda.gov/ cder/foi/nda/2006/022003s000_Noxafil_ClinPharmR.pdf (17 October 2007, date last accessed).